Detalles de la búsqueda
1.
A phase II Japanese trial of 90-minute rituximab infusion for untreated B-cell lymphoma.
Jpn J Clin Oncol;
54(4): 444-451, 2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271157
2.
Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response.
NPJ Syst Biol Appl;
8(1): 39, 2022 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36229495
3.
Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
Cancer Sci;
112(6): 2426-2435, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33792128
4.
Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Cancer Sci;
112(5): 1943-1954, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33576088
5.
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study.
Haematologica;
105(9): 2308-2315, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33054055
6.
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study.
Cancer Med;
9(11): 3742-3751, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32253827
7.
Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group.
Int J Hematol;
111(3): 401-408, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31894533
8.
Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan.
In Vivo;
33(4): 1355-1362, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31280230
9.
Correction to: Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.
Int J Hematol;
108(5): 564, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30168086
10.
Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.
Int J Hematol;
108(5): 524-534, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30043330
11.
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.
Leuk Res;
66: 66-72, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29407585
12.
Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
Leuk Lymphoma;
59(7): 1606-1613, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29081255
13.
Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
Int J Hematol;
105(1): 109-110, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27896571
14.
Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
Int J Hematol;
104(6): 700-708, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27714587
15.
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Oncol Rep;
36(5): 2976-2982, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27665844
16.
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Am J Hematol;
90(9): 819-24, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26103598
17.
[Diffuse large B-cell lymphoma of the testis relapsed 16 years after achieving complete response].
Rinsho Ketsueki;
56(12): 2447-51, 2015 Dec.
Artículo
en Japonés
| MEDLINE | ID: mdl-26725353
18.
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Am J Hematol;
90(4): 282-7, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25530131
19.
Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan.
Haematologica;
99(12): 1817-25, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25216682
20.
Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Cancer Sci;
102(9): 1698-705, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21645173